Why Ensign Group (ENSG) Is Drawing Attention Now
Ensign Group (ENSG) is on investors’ radar after a recent pullback, with the share price showing a 6.4% decline over the past month even as longer term returns remain strong.
That contrast, alongside current revenue of US$5.06b and net income of US$343.97m, is prompting fresh questions about how the market is currently valuing this skilled nursing and senior living operator.
See our latest analysis for Ensign Group.
While the recent 6.4% 30 day share price decline and softer 7 day performance suggest momentum has cooled in the short term, the 1 year total shareholder return of 55.1% and 3 year total shareholder return of 111.78% show a very strong longer term picture. The current US$200.41 share price invites closer scrutiny of how that performance lines up with Ensign Group’s earnings and cash flow profile.
If this kind of move has you reassessing your watchlist, it can be useful to compare Ensign Group with other healthcare names where technology is reshaping care models via the 34 healthcare AI stocks
With revenue of US$5.06b, net income of US$343.97m and a recent pullback from a strong multi year run, the key question is whether Ensign Group is now undervalued or if the market is already pricing in future growth.
Price-to-Earnings of 33.6x: Is It Justified?
Ensign Group is trading on a P/E of 33.6x, which is being treated by the market as a premium price tag relative to both healthcare peers and the wider sector.
The P/E multiple links the current share price of $200.41 to the company’s earnings per share. It effectively shows how many dollars investors are willing to pay for each dollar of earnings. For a skilled nursing and senior living operator with US$5.06b in revenue and US$343.97m in net income, a higher P/E often signals that investors are comfortable paying up for the earnings profile, earnings quality, growth record, or a mix of all three.
Ensign Group’s earnings growth over the past year of 15.4% and 5 year earnings growth of 12.9% per year sit alongside forecasts that earnings may grow 13.22% per year. This could help explain why the market is agreeing to a premium P/E. However, this 33.6x multiple is not only above the US Healthcare industry average of 21.7x, it is also above the peer average of 15.3x and above the estimated fair P/E of 28.9x. This indicates the current level is richer than what the regression based fair multiple suggests and could be an area where expectations eventually normalize toward that lower fair ratio.
Explore the SWS fair ratio for Ensign Group
Result: Price-to-Earnings of 33.6x (OVERVALUED)
However, you also need to consider risks such as regulatory changes around skilled nursing reimbursement, as well as any slowdown in revenue or net income growth, in relation to that 33.6x P/E.
Find out about the key risks to this Ensign Group narrative.
Another View: Cash Flows Point To A Rich Price Too
If the 33.6x P/E looked stretched, the SWS DCF model tells a similar story. On this view, Ensign Group’s estimated future cash flow value is $148.89 per share versus the current $200.41, which implies the stock is trading on the expensive side here.
For investors, that gap raises a simple question: is the premium just a cushion of optimism or a risk that expectations eventually reset toward the DCF mark?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Ensign Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 62 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If this setup feels finely balanced, take a closer look at the underlying data and decide quickly where you stand by reviewing the 2 key rewards.
Looking for more investment ideas?
If Ensign Group is on your radar, do not stop there, some of the most useful opportunities often show up when you compare it directly with targeted stock ideas.
- Start broad and compare Ensign Group with companies that pass quality and value filters by scanning the 62 high quality undervalued stocks.
- Focus on durability and sleep easier by reviewing companies that screen well for financial resilience through the 62 resilient stocks with low risk scores.
- Hunt for potential future favorites before they hit the spotlight by checking the screener containing 25 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com